Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | PYGL | P06737 | 5/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036632 | 0.90 | ACP3 (0.43) | PTGS2ACP3 | |
| SCHEMBL3132378 | 0.87 | PTGS2 (0.48) | PTGS2ACP3CTSAGAAABCB11 | |
| SCHEMBL27660511 | 0.86 | PTGS2 (0.47) | PTGS2ACP3CTSAGAAABCB11 | |
| SCHEMBL7165977 | 0.79 | OPRK1 (0.44) | CXCL8 | |
| SCHEMBL360635 | 0.78 | CXCL8 (0.45) | PTGS2CXCL8GAAABCB11PTGS1 | |
| SCHEMBL2485161 | 0.78 | MEN1 (0.45) | PTGS2GAA | |
| SCHEMBL11271011 | 0.76 | CXCL8 (0.44) | PTGS2CXCL8GAAABCB11PTGS1 | |
| SCHEMBL6809250 | 0.76 | CXCL8 (0.44) | PTGS2CXCL8GAAABCB11PTGS1 | |
| Ammonia Solution, Strong SCHEMBL17997772 | 0.76 | MEN1 (0.44) | PTGS2GAA | |
| SCHEMBL7165891 | 0.76 | SMN1; SMN2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906677-B2 | Process for phenylacetic acid derivatives | NOVARTIS AG (CH) | 2011-03-15 | — | — | US | disclosed |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | ALDH7A1, CYP4F11, CYP2A6 | PTGS2 73/4885PYGL 607/4885PDK1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.